Expert Interviews

CGM is now standard of care in T1D and evidence is solid for a role in insulin-treated T2D; Thomas Martens, MD, shares thoughts on CGM growth in the next 3-5 years.

Martens, medical director of the International Diabetes Center (IDC) in Minneapolis, highlights an IDC resource that helps target problem areas in management of hyperglycemia.

Martens, Director of the International Diabetes Center, in Minneapolis, highlights the differences between the 2 methods and what the research has found on each.

An interview with Jeff Andrews, MD, FRCSC, of BD Life Sciences

ACP 2025: Collaborative care can help address the mental health crisis, but payment and EHR challenges remain. Matthew Press, MD, explains how primary care can overcome these barriers and why integration is essential.

ACP 2025. The timely glucose data available with continuous glucose monitoring is what's needed for optimal daily diabetes control, says Tom Martens, MD.

Panelists discuss how choosing topical treatments requires individualized therapy considering factors such as affected body areas, disease severity, patient age, formulation preferences, and insurance coverage.

Panelists discuss how roflumilast demonstrated good efficacy with 56% to 57% of patients achieving an Investigator’s Global Assessment (IGA) score of 0 or 1 after long-term use, making it effective for maintenance therapy with good tolerability.

Panelists discuss how newer nonsteroidal topical treatments like phosphodiesterase-4 inhibitors (crisaborole and roflumilast), JAK inhibitors (ruxolitinib), and aryl hydrocarbon receptor agonists (tapinarof) are expanding options for atopic dermatitis treatment.

Panelists discuss how long-term use of topical steroids is prevalent with 50% of patients using them 15 to 30 days per month, leading to concerns about adverse effects, including topical steroid withdrawal syndrome.

Panelists discuss how even mild atopic dermatitis can significantly impact quality of life, with 11% of patients with mild symptoms reporting moderate to large impact on their daily functioning.

Panelists discuss how topical steroids should be used intermittently with scheduled breaks to prevent adverse effects like skin atrophy, striae, and telangiectasias.

Panelists discuss how various assessment tools like the IGA, EASI score, and BSA are used to determine the severity of atopic dermatitis and document findings for insurance purposes.

Panelists discuss how atopic dermatitis (AD) affects approximately 7% of adults, has increased by 3% to 5% over the last 5 years, and impacts different body regions depending on age groups.

Panelists discuss how atopic dermatitis presents with red, scaly, itchy, dry, and inflamed skin and is commonly diagnosed in childhood, although it can occur at any age, with frequent flares and comorbid conditions like asthma and allergies.

ACP 2025: Matthew Press, MD, shares actionable steps for primary care physicians to adopt a collaborative care model, including how to start small and partner with other practices.

Issaka, from the Fred Hutch Cancer Center, said insurance coverage, a patient's resources, and social determinants of health all factor in the choice.

ACP 2025: GLP-1 medications are advancing obesity care, but lifestyle changes and bariatric surgery remain key components. Laura Davisson, MD, discusses how to personalize treatment strategies.

ACP 2025: Dr Press discusses how the Penn Integrated Care model equips primary care physicians to manage mental health conditions more effectively while reducing burnout.

ACP 2025: Rachel Issaka, MD, MAS, reviewed data from a Kaiser Permanente program that narrowed racial and ethnic disparities in CRC screening compliance and related deaths.

ACP 2025: Lung cancer is rising among nonsmokers, especially women. Kim Sandler, MD, discusses future screening challenges, research insights, and the need to expand screening eligibility.

ACP 2025: Discover how the collaborative care model supports mental health in primary care through team-based care, symptom tracking, and psychiatric consultation—boosting outcomes and reducing burden on clinicians.

ACP 2025. A focused CRC prevention program begins with primary care where support and advocacy for regular screening begins, Issaka stressed.